AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Marker Therapeutics, Inc. Director's Dealing 2007

Jul 3, 2007

35150_dirs_2007-07-03_8b8c19d9-4ca7-457f-9f13-5de33a47e04c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: TAPIMMUNE INC (TPIM)
CIK: 0001094038
Period of Report: 2007-06-08

Reporting Person: CORIN DENIS (President and CEO)

Holdings (Non-Derivative)

Security	Shares	Ownership
COMMON SHARES	110000	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
OPTIONS	$0.25	2017-06-08	COMMON SHARES (400000)		Direct

Footnotes

F1: 800,000 options to acquire an equivalent number of common shares at $0.25 for 10 years granted; of which 400,000 do not vest until June 8, 2008.

F2: The Issuer's common stock underwent a reverse stock split on June 28, 2007 on a 2.5 old for one new share basis.